Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for MP0317 + Durvalumab + SoC in Advanced cholangiocarcinoma. The expected timing is based on the latest available company guidance and may change.
IIT trial. 11/24- Presented biomarker data at SITC'24. 8/25/25- Ph2 protocol submitted, RA approval pending. 10/30/25- Ph2 protocol approved. 03/12/26:- Ph2 IIT NCT07036380 in advanced cholangiocarcinoma open; two sites activated; dosing ongoing. 05/12/26:- Phase 2 IIT now has eight sites; randomized 75-patient design; treatment ongoing. 07/16/26:- First patients dosed in Ph2 TACTIC (NCT07036380). Data update 2027; trial completion 2028; ESMO 2026 Oct 23-27.
Verification
Confirm timing and program details against the company announcement or filing.